Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 6/28/18 → 3/6/19 |
Funding
- United Therapeutics Corporation: $20,688.00
18-LUN-105-UT (DIV-SCLC-301) A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory SCLC
- Arnold, Susanne (PI)